Actuate Therapeutics Net Income From Continuing Ops Over Time
| ACTU Stock | 4.74 0.23 4.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Actuate Therapeutics Performance and Actuate Therapeutics Correlation. Is there potential for Biotechnology market expansion? Will Actuate introduce new products? Factors like these will boost the valuation of Actuate Therapeutics. If investors know Actuate will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Actuate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actuate Therapeutics is measured differently than its book value, which is the value of Actuate that is recorded on the company's balance sheet. Investors also form their own opinion of Actuate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Actuate Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Actuate Therapeutics' market value can be influenced by many factors that don't directly affect Actuate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Actuate Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Actuate Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Actuate Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Actuate Therapeutics and related stocks such as Seres Therapeutics, Spero Therapeutics, and VistaGen Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCRB | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (141.3 M) | (125.8 M) | (113.2 M) | (118.9 M) |
| SPRO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (32.6 M) | (39.9 M) | (41.7 M) | (60.9 M) | (78.3 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| VTGN | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (47.2 M) | (10.3 M) | (14.3 M) | (24.6 M) | (20.8 M) | (17.9 M) | (47.8 M) | (59.2 M) | (29.4 M) | (51.4 M) | (46.3 M) | (48.6 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.5 M) | (94 M) | (105.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| ELTX | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (12.3 M) | (15.7 M) | (26.4 M) | (28.2 M) | (35.2 M) | (51.9 M) | (46.7 M) | (44.4 M) |
| NKTX | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (274.5 K) | (21.1 M) | (91.4 M) | (86.1 M) | (113.8 M) | (122.3 M) | (108.8 M) | (97.9 M) | (102.8 M) |
| VOR | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (10.8 M) | (43.3 M) | (68.9 M) | (92.1 M) | (115.5 M) | (116.9 M) | (105.2 M) | (100 M) |
| ALEC | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (32.5 M) | (52.2 M) | (105.4 M) | (190.2 M) | (36.3 M) | (133.3 M) | (141.4 M) | (119 M) | (107.1 M) | (112.5 M) |
| MOLN | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (59.6 M) | (54 M) | (62.1 M) | (59 M) |
| PEPG | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (85 M) |
Actuate Therapeutics and related stocks such as Seres Therapeutics, Spero Therapeutics, and VistaGen Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Actuate Therapeutics Common | ACTU |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1751 River Run, |
| Exchange | NASDAQ Exchange |
null 4.74
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.